Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT03546842, this PHASE3 trial focuses on Adenocarcinoma in Situ and Condylomata Acuminata and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .